核定位AR-V7循环肿瘤细胞检测在去势抵抗性前列腺癌治疗选择中的临床效用
该横断面队列纳入193例进展性转移性去势抵抗性前列腺癌(mCRPC)患者,在二线及以上治疗决策时采集255份血样检测循环肿瘤细胞核定位AR-V7,医生对检测结果设盲。调整医生倾向后,AR-V7阳性患者接受紫杉烷类生存优于雄激素受体信号抑制剂(ARSI),AR-V7阴性患者接受ARSI生存更优。
要点
- AR-V7阳性mCRPC患者接受紫杉烷类中位生存9.8个月,优于ARSI的5.7个月(p=0.041)。
- AR-V7阴性患者接受ARSI生存优于紫杉烷类(p=0.033),但生存曲线重叠限制解读。
- 核定位AR-V7检测用于指导治疗选择可改善患者结局。
核心结论
- 使用核定位AR-V7循环肿瘤细胞检测指导治疗选择,相比仅基于标准治疗指标决策,可改善患者结局。
研究设计与样本
- 横断面队列研究,纳入193例进展性mCRPC患者,在二线及以上治疗决策时采集255份血样,随访至多3年。
- 医生对AR-V7状态设盲,检测实验室对结局设盲。
主要发现
- 调整医生倾向后,紫杉烷类与ARSI治疗患者总生存无显著差异(中位15.6 vs 14.4个月;p=0.11)。
- AR-V7阳性患者接受紫杉烷类中位生存9.8个月,优于ARSI的5.7个月(p=0.041)。
- AR-V7阴性患者接受ARSI生存优于紫杉烷类(p=0.033),但曲线重叠限制解读。
- 多变量模型显示AR-V7状态与药物类别存在稳健交互作用,AR-V7阳性男性接受紫杉烷类死亡风险更低。
临床怎么用
- 对二线及以上mCRPC患者,可检测循环肿瘤细胞核定位AR-V7以辅助选择ARSI或紫杉烷类。
- AR-V7阳性者优先考虑紫杉烷类,AR-V7阴性者可考虑ARSI。
局限性
- AR-V7阴性患者生存曲线重叠,限制了解读。
- 研究为横断面队列设计,需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Proof of the clinical utility of a biomarker is when its use informs a management decision and improves patient outcomes relative to when it is not used. OBJECTIVE: To model the clinical benefit of the nuclear-localized androgen receptor splice variant 7 (AR-V7) test for men with progressing metastatic castration-resistant prostate cancer (mCRPC) at the second line of therapy or greater to inform the choice of an androgen receptor signaling inhibitor (ARSI) or a taxane. DESIGN, SETTING, AND PARTICIPANTS: The study population was a cross-sectional cohort of 193 unique patients with progressing mCRPC from whom 255 samples were drawn at the time of the second line or later treatment decision who then received an ARSI or taxane, with up to 3 yr of additional follow-up Circulating tumor cells (CTCs) were identified from blood samples and tested for AR-V7. Physicians were blinded to AR-V7 status and the testing laboratory was blinded to outcomes. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSES: We measured physician propensity for choosing an ARSI or taxane based on patient prognosis. We also measured overall survival (OS) adjusted for physician propensity by drug class; OS data were analyzed both without and with knowledge of nuclear-localized AR-V7 status. RESULTS AND LIMITATIONS: Treating physicians had a propensity for choosing a taxane over an ARSI for patients with more advanced disease or who received an ARSI as the immediate prior therapy. After adjusting for physician propensity, discernible OS differences were not observed between taxane- and ARSI-treated patients (median 15.6 vs 14.4 mo; p =0.11). Patients with detectable nuclear-localized AR-V7 in CTCs had superior survival with taxanes over ARSIs (median 9.8 vs 5.7 mo; p = 0.041). AR-V7-negative patients had superior survival on ARSIs over taxanes (p = 0.033) but overlapping curves limit the interpretation. Mutivariable models showed a robust interaction between AR-V7 status and drug, and a lower risk of death on taxanes for AR-V7-positive men. CONCLUSIONS: Use of the nuclear-localized AR-V7 CTC test to inform treatment choice can improve patient outcomes relative to decisions based solely on standard-of-care measures. PATIENT SUMMARY: Men with metastatic prostate cancer who test positive for AR-V7 protein in circulating tumor cells are likely to live longer if taxane chemotherapy is used.
引用
- Graf RP, Hullings M, Barnett ES, et al. Clinical Utility of the Nuclear-localized AR-V7 Biomarker in Circulating Tumor Cells in Improving Physician Treatment Choice in Castration-resistant Prostate Cancer. Eur Urol. 2019. PMID: 31648903. doi:10.1016/j.eururo.2019.08.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。